Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Integrated Biopharma Inc

OTC: INBP · Life Sciences · 3 alerts · CIK 1016504

Share price
$0.1550Close, Nov 16
Market cap
$4.81M
Shares outstanding
31.06MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Integrated Biopharma Inc filings on SEC EDGAR ↗

12:12 PM ET 8-K
Financial Results

Integrated Biopharma Financial Results

Integrated BioPharma reported a 22% revenue decline to $9.9 million for the quarter ended September 30, 2026, resulting in a net loss of $0.7 million. The company noted significant customer concentration, with its two largest contract manufacturing clients accounting for 88% of total revenue.

Term
Q1 2027

“Our revenue decreased by approximately 22% in the quarter ended September 30, 2026 from the quarter ended September 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 88% and 87% of total revenue in the quarters ended September 30, 2026 and 2025, respectively.”

Riva Sheppard and Christina Kay, Co-Chief Executive Officers
11:52 AM ET 10-Q
Financial Results

Integrated Biopharma Q1 2026 Results: Net Loss of $691K

Integrated BioPharma reported a net loss of $691,000 for the quarter ended September 30, 2026, compared to a net income of $123,000 in the prior year period, driven by a significant decline in net sales from $12.7 million to $9.9 million. The company experienced a gross loss of $112,000 as cost of sales exceeded revenue, leading to a basic and diluted net loss of $0.02 per share.

Key figure
Net loss $691K

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.